Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Lau

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
The Journal of Infectious Diseases|August 19, 2011
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screeningTimothy R Sterling, Bryan Lau, Jinbing Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency VirusMichael J Silverberg, Wendy Leyden, Raúl U Hernández-Ramírez, et al.
The New England Journal of Medicine|April 3, 2009
Effect of early versus deferred antiretroviral therapy for HIV on survivalMari M Kitahata, Stephen J Gange, Alison G Abraham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled TrialShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infectionShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Transfusion|August 3, 2023
Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trialsMoises A Huaman, Jay S Raval, James H Paxton, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent PlasmaDavid J Sullivan, Kelly A Gebo, Shmuel Shoham, et al.
The New England Journal of Medicine|March 30, 2022
Early Outpatient Treatment for Covid-19 with Convalescent PlasmaDavid J Sullivan, Kelly A Gebo, Shmuel Shoham, et al.
JCI Insight|March 14, 2024
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trialHan-Sol Park, Anna Yin, Caelan Barranta, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trialHan-Sol Park, Anna Yin, Caelan Barranta, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
The Journal of Infectious Diseases|August 19, 2011
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screeningTimothy R Sterling, Bryan Lau, Jinbing Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency VirusMichael J Silverberg, Wendy Leyden, Raúl U Hernández-Ramírez, et al.
The New England Journal of Medicine|April 3, 2009
Effect of early versus deferred antiretroviral therapy for HIV on survivalMari M Kitahata, Stephen J Gange, Alison G Abraham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled TrialShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infectionShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Transfusion|August 3, 2023
Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trialsMoises A Huaman, Jay S Raval, James H Paxton, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent PlasmaDavid J Sullivan, Kelly A Gebo, Shmuel Shoham, et al.
The New England Journal of Medicine|March 30, 2022
Early Outpatient Treatment for Covid-19 with Convalescent PlasmaDavid J Sullivan, Kelly A Gebo, Shmuel Shoham, et al.
JCI Insight|March 14, 2024
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trialHan-Sol Park, Anna Yin, Caelan Barranta, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trialHan-Sol Park, Anna Yin, Caelan Barranta, et al.
Pageof 19